Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Charles River Laboratories Intl
(NY:
CRL
)
203.30
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Charles River Laboratories Intl
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 22, 2023
Via
Benzinga
Jim Cramer Says This Stock Is Undervalued: 'I Think That It's Coming Back'
February 02, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer he wants to own Sherwin-Williams Co (NYSE: SHW). "Everything that they could possibly say negative about it is out there.
Via
Benzinga
Charles River Laboratories, AbbVie, Star Bulk Carriers And This Big Bank Are CNBC's 'Final Trades'
January 23, 2023
On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said Charles River Laboratories International, Inc. (NYSE: CRL) is trading at 20 time
Via
Benzinga
This Favorable Sign Appears On Charles River's Chart
January 19, 2023
Via
Benzinga
What Does Charles River's Debt Look Like?
January 12, 2023
Over the past three months, shares of Charles River Inc. (NYSE:CRL) increased by 16.70%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its...
Via
Benzinga
Why Charles River Laboratories Stock Is Jumping Today
November 02, 2022
Investors liked the company's Q3 update.
Via
The Motley Fool
Expert Ratings for Charles River
September 30, 2022
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings:
Via
Benzinga
5 Analysts Have This to Say About Charles River
September 30, 2022
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings:
Via
Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Analyst Ratings for Charles River
November 03, 2022
Over the past 3 months, 5 analysts have published their opinion on Charles River (NYSE:CRL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday
November 03, 2022
U.S. stocks closed lower on Wednesday, with the Dow Jones dropping more than 500 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Charles River: Q3 Earnings Insights
November 02, 2022
Charles River (NYSE:CRL) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Charles River beat estimated...
Via
Benzinga
Where Charles River Stands With Analysts
September 30, 2022
Charles River (NYSE:CRL) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Expert Ratings for Charles River
August 25, 2022
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings:
Via
Benzinga
Recap: Charles River Q2 Earnings
August 03, 2022
Charles River (NYSE:CRL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
November 03, 2022
Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
Via
Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
November 02, 2022
Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.
Via
Benzinga
Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies
October 25, 2022
Medpace earnings soared in Q3 as weakness in contract awards turned to strength, sending MEDP stock surging.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 18, 2022
Gainers
Via
Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
October 03, 2022
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Via
Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
September 30, 2022
Gainers
Via
Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
September 30, 2022
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022
September 30, 2022
Upgrades
Via
Benzinga
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
September 30, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock.
Via
Benzinga
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
August 16, 2022
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
August 25, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022
August 04, 2022
Upgrades
Via
Benzinga
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday
August 03, 2022
Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results.
Via
Benzinga
'I'm Going To Have To Say Avoid It': Jim Cramer Urges Waiting Before Buying This Tech Stock
August 02, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Charles River Laboratories International Inc (NYSE: CRL).
Via
Benzinga
Where Charles River Stands With Analysts
July 14, 2022
Over the past 3 months, 5 analysts have published their opinion on Charles River (NYSE:CRL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.